TARDBP and amyotrophic lateral sclerosis: Together, these new tools facilitate the detection of a wider range of pathological events compared to classical antibody approaches alone, providing crucial insights in ALS including early nuclear TDP-43 aggregation preceding cytoplasmic mislocalisation (59), and evidence of TDP-43 pathology in SOD1-ALS (59).